The Insider of Fluidigm (FLDM), Levin Capital Strategies – L.P. Bought 16,900 Shares; CASI Pharmaceuticals, Inc. (CASI) Covered By 2 Bulls

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Logo

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 6 analyst reports since October 29, 2015 according to SRatingsIntel. H.C. Wainwright initiated it with “Buy” rating and $3 target in Thursday, October 29 report. Maxim Group maintained the stock with “Buy” rating in Monday, August 14 report. H.C. Wainwright maintained CASI Pharmaceuticals, Inc. (NASDAQ:CASI) rating on Wednesday, April 4. H.C. Wainwright has “Buy” rating and $700 target. H.C. Wainwright maintained the shares of CASI in report on Tuesday, January 16 with “Buy” rating. The company was initiated on Thursday, September 22 by Maxim Group. See CASI Pharmaceuticals, Inc. (NASDAQ:CASI) latest ratings:

04/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.5 Maintain

Fluidigm Corporation (NASDAQ:FLDM) Ratings Coverage

Among 5 analysts covering Fluidigm (NASDAQ:FLDM), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Fluidigm has $28 highest and $4.4 lowest target. $12.62’s average target is 121.02% above currents $5.71 stock price. Fluidigm had 22 analyst reports since August 7, 2015 according to SRatingsIntel. On Friday, August 5 the stock rating was maintained by Mizuho with “Buy”. As per Friday, October 30, the company rating was upgraded by Cantor Fitzgerald. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Neutral” rating by Mizuho on Friday, October 30. The rating was maintained by Piper Jaffray on Thursday, August 3 with “Hold”. Cowen & Co maintained it with “Hold” rating and $7.25 target in Wednesday, December 20 report. Piper Jaffray downgraded the stock to “Neutral” rating in Friday, August 7 report. The stock has “Buy” rating by Mizuho on Friday, February 5. The firm earned “Hold” rating on Thursday, August 27 by Maxim Group. The firm has “Outperform” rating by Cowen & Co given on Friday, October 2. On Thursday, January 7 the stock rating was initiated by Deutsche Bank with “Buy”.

The stock increased 2.51% or $0.14 during the last trading session, reaching $5.71. About 174,867 shares traded. Fluidigm Corporation (NASDAQ:FLDM) has risen 7.86% since May 14, 2017 and is uptrending. It has underperformed by 3.69% the S&P500.

Since December 11, 2017, it had 24 buys, and 0 sales for $6.00 million activity. LEVIN CAPITAL STRATEGIES – L.P. also bought $5,928 worth of Fluidigm Corporation (NASDAQ:FLDM) shares.

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research. The company has market cap of $222.21 million. It offers preparatory instruments, such as access array system, juno system, and callisto system; analytical instruments comprising biomark HD and EP1 systems; integrated fluidic circuits consisting of access array, juno genotyping, dynamic array, digital array, flex six, and callisto IFCs; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. It currently has negative earnings. The firm also provides C1 single-cell systems, polaris systems, C1 IFCs, polaris IFCs, helios/CyTOF 2 systems, maxpar reagents, imaging mass cytometer instruments and reagents, and laser ablation modules.

Investors sentiment increased to 1.61 in Q4 2017. Its up 0.03, from 1.58 in 2017Q3. It is positive, as 9 investors sold Fluidigm Corporation shares while 19 reduced holdings. 15 funds opened positions while 30 raised stakes. 32.56 million shares or 0.48% more from 32.41 million shares in 2017Q3 were reported. Voya Inv Management Limited Liability Co invested in 0% or 15,901 shares. Parametric Port Associates Ltd holds 0% or 37,269 shares. Millennium Management Llc has invested 0% in Fluidigm Corporation (NASDAQ:FLDM). Bnp Paribas Arbitrage invested 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM). Bridgeway holds 73,572 shares. Pub Employees Retirement Systems Of Ohio reported 45,664 shares or 0% of all its holdings. 1.32M are held by Vanguard Inc. Tower Research Lc (Trc) holds 0.01% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM) for 9,817 shares. Wasatch Advsr owns 221,531 shares. Legal General Group Public owns 0% invested in Fluidigm Corporation (NASDAQ:FLDM) for 9,571 shares. Rhumbline Advisers reported 27,941 shares. Illinois-based Citadel Advisors Ltd Llc has invested 0% in Fluidigm Corporation (NASDAQ:FLDM). Renaissance Technology Limited Liability reported 805,300 shares stake. Acadian Asset Mgmt Ltd Llc holds 146,705 shares or 0% of its portfolio. Manufacturers Life Insurance The invested 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM).

After the publishing of a document filled with Washington-based SEC; deal became apparent. The insider of Fluidigm Corp, Levin Capital Strategies – L.P.; performed a purchase in the open market by accumulating 16,900 shares at the average share price which was $5.4 of the Pinksheet-listed company valued at near $90,836 U.S Dollars. This transaction decreased his ownership of the company to 32.66% market cap or 12.71 million shares.

More notable recent Fluidigm Corporation (NASDAQ:FLDM) news were published by: which released: “Fluidigm to Participate in Upcoming Investor Events” on May 09, 2018, also with their article: “Fluidigm Announces First Quarter Financial Results and Operational Progress” published on May 03, 2018, published: “Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations” on April 23, 2018. More interesting news about Fluidigm Corporation (NASDAQ:FLDM) were released by: and their article: “Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” published on May 10, 2018 as well as‘s news article titled: “Fluidigm to Report Q1 2018 Financial Results and Host Conference Call” with publication date: April 19, 2018.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $696.38 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

The stock increased 2.93% or $0.23 during the last trading session, reaching $8.09. About 356,180 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has risen 181.56% since May 14, 2017 and is uptrending. It has outperformed by 170.01% the S&P500.

Fluidigm Corporation (NASDAQ:FLDM) Institutional Positions Chart